Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.
What's holding back value-based pricing deals from moving beyond the pilot phase?
The goal is to further cement point of care as a mainstream media channel.
Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.
A particular focus is put on the emerging research about cannabis and its benefits for the human body.
It's the third year of consecutive growth for spending on accredited CME, according to the Accreditation Council for Continuing Medical Education.
Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.
The deal highlights ongoing interest in the influential point-of-care market.
Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.